All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 150 of 206 pages ‹ First < 148 149 150 151 152 > Last ›
HSL1797
Zimmerman HM.
Rx for compliance. How the new PhRMA code on permissible pharmaceutical marketing practices affects your organization
MGMA Connex. 2003 Feb 01;3:(2):54-7, 1.
HSL16246
Cloutier-Steele L
Misinformed Consent: Women's Stories about Unnecessary Hysterectomy : Next Decade, Inc 2003
http://www.findings.net/misinformedconsent.html
HSL1209
Giaquinta D.
The changing timetable for the evaluation of new products for formulary consideration.
Manag Care Interface 2003 Feb;16:(2):24-5,
HSL1230
Cleophas GC, Cleophas TJ.
Clinical trials in jeopardy.
Int J Clin Pharmacol Ther 2003 Feb;41:(2):51-5
HSL1243
Bernath P.
Regulation of online pharmacy: an Australian perspective.
J Law Med 2003 Feb;10:(3):339-63
HSL1252
Allison-Ottey S, Ruffin K, Allison K, Ottey CC.
Assessing the impact of direct-to-consumer advertisements on the AA patient: a multisite survey of patients during the office visit.
J Natl Med Assoc 2003 Feb;95:(2):120-31
HSL2081
Prosser H, Almond S, Walley T.
Influences on GPs' decision to prescribe new drugs-the importance of who says what.
Fam Pract 2003 Feb;20:(1):61-8
http://fampra.oxfordjournals.org/cgi/content/full/20/1/61
HSL2137
Watkins C, Harvey I, Carthy P, Moore L, Robinson E, Brawn R.
Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey.
Qual Saf Health Care 2003 Feb;12:(1):29-34
http://qhc.bmjjournals.com/cgi/content/full/12/1/29
HSL10543
Lee EK, Malone DC.
Comparison of peptic-ulcer drug use and expenditures before and after the implementation of a government policy to separate prescribing and dispensing practices in South Korea.
Clin Ther 2003 Feb;25:(2):578-92
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRS-48SYGR4-15&_user=10&_coverDate=02%2F28%2F2003&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=d303d0228b3eb301dc1977897b49ca5ehttp://
HSL10617
Crowe S, Fitzpatrick G.
Making herbal medicines safe.
Anaesthesia 2003 Feb;58:(2):184-5
HSL10619
Lee WS, Puthucheary SD, Parasakthi N, Choo KE.
Antimicrobial susceptibility and distribution of non-typhoidal Salmonella serovars isolated in Malaysian children.
J Trop Pediatr 2003 Feb;49:(1):37-41
http://tropej.oxfordjournals.org/cgi/reprint/49/1/37http://
HSL10622
Khurana RN, Lee PP, Challa P.
Readability of ocular medication inserts.
J Glaucoma 2003 Feb;12:(1):50-3
http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1057-0829&volume=12&issue=1&spage=50
HSL10630
Jacoby A, Smith M, Eccles M.
A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs.
Br J Gen Pract 2003 Feb;53:(487):120-5
http://www.ingentaconnect.com/content/rcgp/bjgp/2003/00000053/00000487/art00008?token=005117d8d7adad8726e2d2954496f642f466f256720297d7625627b504a5f245a38532c2bd029ec17
HSL10631
Schirm E, Tobi H, de Jong-van den Berg LT.
Risk factors for unlicensed and off-label drug use in children outside the hospital.
Pediatrics 2003 Feb;111:(2):291-5
http://pediatrics.aappublications.org/cgi/content/full/111/2/291
HSL13261
Paswan AK, Kulkarni S, Ganesh G.
Loyalty towards the country, the state and the service brands
Journal of Brand Management (2003) 10, 2003 Feb;10:(3):233–251
http://www.palgrave-journals.com/bm/journal/v10/n3/abs/2540119a.html
HSL17925
Abelson R
Drug Sales Bring Huge Profits, and Scrutiny, to Cancer Doctors
The New York Times 2003 Jan 26
http://www.nytimes.com/2003/01/26/us/drug-sales-bring-huge-profits-and-scrutiny-to-cancer-doctors.html?sec=health
HSL18264
Burton B
Changing prescription software to favour generics could save Australia £40m a year
BMJ 2003 Jan 25;326:(7382):184
http://www.bmj.com/cgi/content/extract/326/7382/184/b
HSL18265
Ed.
Whose interests does the World Trade Organization serve
Lancet 2003 Jan 25;
http://www.lancet.com/journals/lancet/article/PIIS0140-6736(03)12360-4/fulltext
HSL1009
Abelson R.
Asthma Drug Health Risks Are Suspected, Company Says
The New York Times 2003 Jan 24
http://www.nytimes.com/2003/01/24/us/asthma-drug-health-risks-are-suspected.html
HSL17920
Unethical Pizza
The Washington Post 2003 Jan 23
HSL18263
Marwick C
FDA halts gene therapy trials after leukaemia case in France
BMJ 2003 Jan 23;326:(7382):181
http://www.bmj.com/cgi/content/extract/326/7382/181/a
HSL17924
Pharmaceutical Industry Ties with Academic Researchers May 'Skew' Study Results
California Healthline 2003 Jan 22
http://www.nytimes.com/2003/01/24/us/asthma-drug-health-risks-are-suspected.html
HSL18262
Bekelman JE, Yan Li, and Gross, CP
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
JAMA 2003 Jan 22;289:(4):454
http://jama.ama-assn.org/cgi/content/abstract/289/4/454
HSL18266
Mello MM, Rosenthal M, Neumann PJ.
Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers.
JAMA 2003 Jan 22-29;289:(4):477-81
http://jama.ama-assn.org/cgi/content/full/289/4/477
HSL17922
Hallam K
Drugmakers to Oppose Maine Discount Law at U.S. Supreme Court
Bloomberg News 2003 Jan 21
HSL17923
Hayes E
European Patients Often Denied Innovative Drugs
Reuters Health 2003 Jan 21
HSL18272
Cassels A
Europe rejects pitch for direct-to-consumer drug ads
CMAJ 2003 Jan 21;168:(2):209
http://www.cmaj.ca/cgi/reprint/168/2/209
HSL18268
Gottlieb S
FDA insists that oestrogen products for menopause carry a warning
BMJ 2003 Jan 18;326:(7381):126
http://www.bmj.com/cgi/content/extract/326/7381/126/a
HSL18269
Waterston T, Tumwine J
Monitoring the marketing of infant formula feeds
BMJ 2003 Jan 18;326:(7381):113-4
http://www.bmj.com/cgi/content/extract/326/7381/113
HSL18270
Dobson R
Lack of new drugs is reaching crisis point, says review
BMJ 2003 Jan 18;326:(7381):119
http://www.bmj.com/cgi/content/extract/326/7381/119
HSL18271
Kmietowicz Z
Medicines Control Agency must be more open
BMJ 2003 Jan 18;326:(7381):119
http://www.bmj.com/cgi/content/extract/326/7381/119/a
HSL18273
Lenzer J
Marketing: Spin doctors soft pedal data on antihypertensives
BMJ 2003 Jan 18;326:(7381):170
http://www.bmj.com/cgi/content/full/326/7381/170/DC1
HSL18274
Moynihan R
Company launches campaign to 'counter' BMJ claims
BMJ 2003 Jan 18;326:(7381):120
http://www.bmj.com/cgi/content/extract/326/7381/120/a
HSL1008
18 Deaths Linked to drug - Serzone Removed from European market, not US
2003 Jan 17
HSL1007
Davies N, Arlington S.
Powering up the pipeline
Source: Pharmafocus 2003 Jan 16
HSL17921
Hagan P
General practitioners deciding whether to prescribe a new drug are more likely to rely on information supplied by the representative from the pharmaceutical firm that makes it than independent sources of evidence, according to a new British study.
Reuters Health 2003 Jan 16
HSL10519
Shah ND, Hoffman JM, Vermeulen LC, Hunkler RJ, Hontz KM.
Projecting future drug expenditures--2003.
Am J Health Syst Pharm 2003 Jan 15;60:(2):137-49
http://www.ajhp.org/cgi/reprint/60/2/137
HSL1006
Hensley S.
Doctor Continuing-Ed Overseer To Tackle Drug Firm Influence
Staff Reporter of The Wall Street Journal 2003 Jan 14
http://online.wsj.com/article/SB104249837652326024.html?mod=googlewsj
HSL17918
Japsen B
Abbott freezes salaries to pay for drug launch
Chicago Tribune 2003 Jan 14
HSL17919
Kumar A
Doctors Split on Usefulness of Drug Advertising: FDA survey highlights debate about whether feel-good TV and print notices raise awareness or sway patients to seek care they don't need.
The New York Times 2003 Jan 14
http://articles.latimes.com/2003/jan/14/nation/na-doctors14
HSL17422
Erskine D
Demand for Schering to pay NHS compensation for
Scrip 2003 Jan 13;
HSL17423
Lueck S, Baglone J
Glaxo Says It Will Retaliate Against Cross-Border Sales
The Wall Street Journal 2003 Jan 13
http://online.wsj.com/article/SB1042245470898700224.html?mod=googlewsj
HSL18275
Sutcliffe AG
Testing New Pharmaceutical Products in Children
BMJ 2003 Jan 11;326:(7380):64-65
http://www.bmj.com/cgi/content/extract/326/7380/64
HSL18276
Marwick C
US doctor warns of misuse of prescribed stimulants
BMJ 2003 Jan 11;326:(7380):67
http://www.bmj.com/cgi/content/extract/326/7380/67
HSL1570
European 'Direct-to-Consumer' Drug Information Plans May Face Opposition
Reuters Health 2003 Jan 10
HSL1005
Kolata G.
F.D.A. Orders Warning on All Estrogen Labels
New York Times 2003 Jan 9
HSL17421
Patients Trust Doctors' Judgment Despite Pushy Drug Marketing
The Wall Street Journal 2003 Jan 9
HSL1004
Renton T.
No publicity is bad publicity, especially when it comes in the guise of an educational magazine
Rabble News www.rabble.ca 2003 Jan 8
http://www.rabble.ca/news_full_story.shtml?sh_itm=79647aed5538a4d5ddc4579df19d6dae&r=1
HSL1003
Pfizer To Pay $6M To Settle Investigation into Marketing Tactics for Children's Antibiotic
Kaiser Daily Report www.kaisernetwork.org 2003 Jan 7
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=15374
HSL17420
Burton TM
Abbott to Offer Humira Free To Some Medicare Recipients
The Wall Street Journal 2003 Jan 7
http://online.wsj.com/article/SB1041892019490109864.html?mod=googlewsj
HSL1001
Drugs companies accused over adverts
BBC News 2003 Jan 6
HSL10640
Eadie MJ.
Withdrawal of methylphenobarbitone.
Med J Aust 2003 Jan 6;178:(1):44
HSL1000
Holland J.
MedicAlert lifeline lent to patients in drug trials
2003 Jan 5
HSL1214
Floyd T.
Conflict of interest courtesy of drug reps...
BMJ 2003 Jan 5;325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL1176
Villanueva P, Peiro S, Librero J, Pereiro I.
Accuracy of pharmaceutical advertisements in medical journals.
Lancet 2003 Jan 4;361:(9351):27-32
http://linkinghub.elsevier.com/retrieve/pii/S0140673603121186
HSL1215
Fletcher RH.
Adverts in medical journals: caveat lector.
Lancet 2003 Jan 4;361:(9351):10-1
http://www.thelancet.com/journal/vol361/iss9351/full/llan.361.9351.editorial_and_review.23889.1
HSL3809
Moynihan R.
The making of a disease: female sexual dysfunction.
BMJ 2003 Jan 4;326:(7379):45-7
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=12511464
HSL18277
Ford N, 't Hoen E, McKee M
Trade concerns must not be allowed to set the public health agenda
Lancet 2003 Jan 4;361:(9351):71 - 72
http://www.lancet.com/journals/lancet/article/PIIS0140-6736(03)12123-X/fulltext?version=printerFriendly
HSL18278
Sweet M
Lessons from the HRT story
BMJ 2003 Jan 4;326:(7379):58
http://www.bmj.com/cgi/content/full/326/7379/58
HSL996
Kirkey S.
Relief from hot flashes can come from anti-depressants
CanWest News Service 2003 Jan 3
HSL997
California Group Claims Pharmacia Illegally Promoted Pain Treatment Bextra for Off-Label Uses
The California Healthline 2003 Jan 3
HSL998
Bush Administration's Proposed Physician Gift Guidelines Criticized by Pharmaceutical Industry
California Healthline 2003 Jan 3
HSL999
Mokhiber R.
The 10 Worst Corporations of 2002
Focus on the Corporation 2003 Jan 3
http://www.multinationalmonitor.org/mm2002/02december/dec02corp1.html
HSL1187
Marcus , Erin N.
When TV commercials play the doctor
The New York Times 2003 Jan 3
http://www.nytimes.com/2003/01/03/opinion/03MARC.html
HSL1195
Kristiansen IS.
Broadening the concept of competing interests
BMJ 2003 Jan 3;325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL3681
Meek C.
Direct-to-consumer advertising (DTCA) of Prescription Medicines: Fourth Quarterly UpdatedOctober to December 2002.
London: Royal Pharmaceutical Society of Great Britain 2003 Jan 3
http://www.rpsgb.org/pdfs/dtcarev0212.pdf
HSL1612
Wood W, Quinn JM.
Forewarned and forearmed? Two meta-analytic syntheses of forewarnings of influence appeals
Psychol Bull 2003 Jan;129:(1):119-138
http://content.apa.org/journals/bul/129/1/119
HSL4530
Cassels A.
February is Heart Month.
Common Ground (Vancouver) 2003 Jan 1
http://www.commonground.ca/iss/0602175/cg175_cassels.shtml
HSL5414
Helgason T, Tomasson K, Zoega T.
[Prevalence and distribution of antidepressant, anxiolytic and hypnotic use in 2001].
Laeknabladid 2003 Jan 01;89:(1):15-22
HSL7655
Roth JM.
Direct-to-consumer advertising of controlled substances.
Am J Health Syst Pharm 2003 Jan 1;60:(1):91-2
http://www.ajhp.org/cgi/pmidlookup?view=reprint&pmid=12533985
HSL17419
Goldberg M, Davenport B, Mortellito T
When Will the Bubble Burst?: Despite a struggling economy, Pharma companies continue to raise the rewards for sales reps and product managers.
Pharmaceutical Executive 2003 Jan 1
HSL1181
Stokamer CL.
Pharmaceutical gift giving: analysis of an ethical dilemma.
J Nurs Adm 2003 Jan;33:(1):48-51
HSL1212
Gahart MT, Duhamel LM, Dievler A, Price R.
Examining the FDA's oversight of direct-to-consumer advertising.
Health Aff (Millwood) 2003 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.120v1
HSL1218
Evans GR, Packham DE.
Ethical issues at the university-industry interface: a way forward?
Sci Eng Ethics 2003 Jan;9:(1):3-16
HSL1220
Dubois RW.
Pharmaceutical promotion: don't throw the baby out with the bathwater.
Health Aff (Millwood) 2003 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.96v1
HSL1235
Calfee JE.
What do we know about direct-to-consumer advertising of prescription drugs?
Health Aff (Millwood) 2003 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.116v1
HSL1241
Bodenheimer T.
Two advertisements for TV drug ads.
Health Aff (Millwood) 2003 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.112v1
HSL1242
Bircher AJ, Surber C.
Unregulated alternative medicine.
J Drugs Dermatol 2003 Jan;2:(1):58-61
HSL1245
Batchlor E, Laouri M.
Pharmaceutical promotion, advertising, and consumers.
Health Aff (Millwood) 2003 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.109v1
HSL1249
Avorn J.
Advertising and prescription drugs: promotion, education, and the public's health.
Health Aff (Millwood) 2003 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.104v1
HSL1800
Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R.
Consumers' reports on the health effects of direct-to-consumer drug advertising.
Health Aff (Millwood) 2003 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.82v1
HSL1801
Weatherall D.
Problems for biomedical research at the academia-industrial interface.
Sci Eng Ethics 2003 Jan;9:(1):43-8
HSL1803
Vogel RJ, Ramachandran S, Zachry WM.
A 3-stage model for assessing the probable economic effects of direct-to-consumer advertising of pharmaceuticals.
Clin Ther 2003 Jan;25:(1):309-29
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRS-4833JPP-S&_coverDate=01%2F31%2F2003&_alid=295787923&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6242&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=dba690738e220c9c57bacf614e822901
HSL4720
Mamdani B.
He's ethical but has bad taste...
Issues Med Ethics 2003 Jan-Mar;11:(1):24
HSL7650
Bjerrum L, Foged A.
Patient information leaflets--helpful guidance or a source of confusion?
Pharmacoepidemiol Drug Saf 2003 Jan-Feb;12:(1):55-9
HSL9939
Wiggins WP.
Pfizer-Pharmacia: the smart fit for the future.
Expert Opin Investig Drugs 2003 Jan;12:(1):1-3
http://www.expertopin.com/doi/abs/10.1517/13543784.12.1.1
HSL10634
Boos J.
Off label use--label off use?
Ann Oncol 2003 Jan;14:(1):1-5
http://annonc.oxfordjournals.org/cgi/content/full/14/1/1
HSL10641
Thomas N, Fifer SK.
The combination of collaborative drug therapy management and E-prescribing.
Manag Care Interface 2003 Jan;16:(1):38-42,
HSL10649
Cimons M.
Drug costs threaten patent protection.
Nat Med 2003 Jan;9:(1):9
http://www.nature.com/doifinder/10.1038/nm0103-9b
HSL10653
Singer RS, Finch R, Wegener HC, Bywater R, Walters J, Lipsitch M.
Antibiotic resistance--the interplay between antibiotic use in animals and human beings.
Lancet Infect Dis 2003 Jan;3:(1):47-51
http://linkinghub.elsevier.com/retrieve/pii/S1473309903004900
HSL16746
Wolfe SM.
Remedies needed to address the pathology in reporting adverse reactions and Food and Drug Administration use of reports.
J Gen Intern Med 2003 Jan;18:(1):72-3
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1494800/?tool=pubmed
HSL192
Katz D, Caplan AL, Merz JF.
All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving.
Am J Bioeth 2003;3:(3):39-46
http://www.ingentaconnect.com/content/routledg/ajob/2003/00000003/00000003/art00027
HSL1174
Williams-Jones B, Corrigan OP.
Rhetoric and hype: where's the 'ethics' in pharmacogenomics?
Am J Pharmacogenomics 2003;3:(6):375-83
HSL1175
Wager E, Field EA, Grossman L.
Good publication practice for pharmaceutical companies.
Curr Med Res Opin 2003;19:(3):149-54
HSL1180
Tsai AC.
Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals.
Int J Health Serv 2003;33:(4):751-68
HSL1190
Manima A.
Ethical issues in palliative care: considerations.
J Pain Palliat Care Pharmacother 2003;17:(3-4):141-9;
HSL1205
Hill S, Freemantle N.
A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data
Pharmacoeconomics. 2003;21:(11):761-7
HSL1216
Fisher MA.
Physicians and the pharmaceutical industry: a dysfunctional relationship.
Perspect Biol Med 2003 Spr;46:(2):254-72
http://www.ncbi.nlm.nih.gov/pubmed/12721524
HSL1224
Desmet C.
Pharmaceutical firms' generosity and physicians: legal aspects in Belgium.
Med Law 2003;22:(3):473-87
http;//www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14626881
HSL1226
de Lissovoy G.
Weighing the evidence: trends in managed care formulary decision making.
J Clin Psychiatry 2003;64:
http://www.unboundmedicine.com/evidence/ub/citation/14680425/Weighing_the_evidence:_trends_in_managed_care_formulary_decision_making_
Page 150 of 206 pages ‹ First < 148 149 150 151 152 > Last ›
